Outlook Therapeutics

OTLKNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$169.488 M

$0.70 +1.44%

Close of 22 Sept 2026

Revenue

$1.41M

#3450 by revenue

Earnings

-$62.4M

Loss-making

Shares outstanding

243,447,554

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#101Voyager TherapeuticsVYGR$193.5M
#102Acumen PharmaceuticalsABOS$191.6M
#103Outlook TherapeuticsOTLK$169.5M
#104HumacyteHUMA$161.9M
#105Molecular PartnersMOLN$159.8M

Insiders buying

All insider buying →

4 open-market purchases by officers and directors of Outlook Therapeutics, worth $2.60M. Grants and option exercises are excluded.

GMS Ventures & Investments, Ghiath M. Sukhtian$2.50M
2,525,252 shares at $0.99 on 12 Aug 2026 · filed 14 Aug 2026
Robert Charles JahrChief Executive Officer$0.00
151,515 shares on 14 Aug 2026 · filed 14 Aug 2026
Lawrence A. KenyonChief Financial Officer$0.00
101,010 shares on 14 Aug 2026 · filed 14 Aug 2026
Faisal Ghiath Sukhtian$100.0K
95,398 shares at $1.05 on 29 Jul 2026 · filed 29 Jul 2026

What if Outlook Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$124,190.90

Per share 178,384× higher

Bitcoin $1.74T

$7,154.13

Per share 10,276× higher

Nvidia $5.52T

$22,656.90

Per share 32,544× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Outlook Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.